Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01218867 | CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer | terminated | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT01369875 | Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Dec 10, 2019 | clinicaltrials |
| NCT02190838 |
| Comparison of Melatonin or Metformin and Dacarbazine Combination Versus Dacarbazine Alone in Disseminated Melanoma |
| terminated |
| Phase 2 |
| 57 |
| N.N. Petrov National Medical Research Center of OncologyOTHER |
| 1 |
| Nov 25, 2019 |
| clinicaltrials |
| NCT01585415 | Vemurafenib and White Blood Cell Therapy for Advanced Melanoma | terminated | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT00670748 | Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer | terminated | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01264081 | Lapatinib in Stage IV Melanoma With ERBB4 Mutations | terminated | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 1 | Nov 13, 2019 | clinicaltrials |
| NCT02744209 | Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients | terminated | — | 17 | Mayo ClinicOTHER | 1 | Nov 7, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02359851 | Pembrolizumab in Treating Patients With Advanced Uveal Melanoma | terminated | Phase 2 | 5 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02302339 | A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | terminated | Phase 2 | 132 | Celldex TherapeuticsINDUSTRY | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01471054 | Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma | terminated | Phase 2 | 6 | Arman MashayekhiOTHER | 1 | Sep 3, 2019 | clinicaltrials |
| NCT00729807 | 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma | terminated | Phase 2 | 6 | University of Maryland, BaltimoreOTHER | 1 | Aug 16, 2019 | clinicaltrials |
| NCT00346372 | Optical Coherence Tomography of Retinal Abnormalities Associated With Choroidal Nevus, Choroidal Melanoma and Choroidal Melanoma Treated With Iodine-125 Brachytherapy | terminated | — | 5 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2019 | clinicaltrials |
| NCT00571116 | Disulfiram Plus Arsenic Trioxide In Patients With Metastatic Melanoma and at Least One Prior Systemic Therapy | terminated | Phase 1 | 9 | University of California, IrvineOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT03552549 | SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002) | terminated | Phase 2 / Phase 3 | 126 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 24, 2019 | clinicaltrials |
| NCT02891616 | 18F-FLT PET Imaging in Patients With Advanced Melanoma | terminated | Phase 1 | 4 | Washington University School of MedicineOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT02005614 | A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection | terminated | N/A | 39 | Yale UniversityOTHER | 1 | Jul 1, 2019 | clinicaltrials |
| NCT02153905 | T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01875653 | Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma | terminated | Phase 3 | 4 | Lisata Therapeutics, Inc.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice(N1) | terminated | — | 23 | CureOneOTHER | 1 | Apr 2, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01813214 | The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma | terminated | Phase 2 | 5 | Georgetown UniversityOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT02339987 | Procure Tumor and Initiate Melanoma Tumor-Reactive Tumor Infiltration | terminated | — | 27 | Saint John's Cancer InstituteOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT02314143 | Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib | terminated | Phase 2 | 48 | GlaxoSmithKlineINDUSTRY | 2 | Feb 18, 2019 | clinicaltrials |
| NCT01542255 | Metronomic Therapy in Patients With Metastatic Melanoma | terminated | Phase 2 | 7 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01350401 | Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 4 | AdaptimmuneINDUSTRY | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01457131 | Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02050321 | A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma | terminated | Phase 2 | 2 | University of ArizonaOTHER | 1 | Dec 26, 2018 | clinicaltrials |
| NCT00929019 | Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients | terminated | Phase 1 / Phase 2 | 23 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT02327390 | Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma | terminated | Phase 1 | 3 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT00540969 | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases | terminated | Phase 3 | 3 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 21, 2018 | clinicaltrials |
| NCT00791271 | Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 9, 2018 | clinicaltrials |
| NCT01814046 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma | terminated | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01876641 | Treatment of a Resistant Disease Using Decitabine Combined With Vemurafenib Plus Cobimetinib(ML28604) | terminated | Phase 1 | 18 | Mohammed M MilhemOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT00039091 | Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer | terminated | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 5, 2018 | clinicaltrials |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors | terminated | Phase 1 | 4 | Mayo ClinicOTHER | 1 | Sep 5, 2018 | clinicaltrials |
| NCT00961376 | Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) | terminated | Phase 2 | 5 | Providence Health & ServicesOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01636960 | A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370) | terminated | Phase 1 | 9 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT03073473 | Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers | terminated | — | 40 | Cota Inc.INDUSTRY | 1 | Jul 20, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
| NCT01341496 | Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal | terminated | Phase 1 | 41 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02113683 | Validation of MMS Test for Cancer Monitoring(MMS-TM) | terminated | — | 100 | MedInnovation GmbHINDUSTRY | 1 | Jun 21, 2018 | clinicaltrials |
| NCT01453361 | Phase II FANG™ in Advanced Melanoma | terminated | Phase 2 | 18 | Gradalis, Inc.INDUSTRY | 1 | May 24, 2018 | clinicaltrials |
| NCT01533948 | Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT02543645 | A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer | terminated | Phase 1 | 18 | Celldex TherapeuticsINDUSTRY | 1 | Apr 30, 2018 | clinicaltrials |
| NCT01702896 | Interleukin-2 in Metastatic Melanoma | terminated | Phase 2 | 8 | Western Regional Medical CenterOTHER | 1 | Apr 5, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Dec 10, 2019source: clinicaltrials